After nearly four decades of research, a safe and effective HIV-1 vaccine remains elusive.
There are many reasons why the development of a potent and durable HIV-1 vaccine is …

Although immunotherapy research to date has focused largely on T cells, there is mounting
evidence that tumour-infiltrating B cells and plasma cells (collectively referred to as tumour …

The transcription factor NF-κB regulates multiple aspects of innate and adaptive immune
functions and serves as a pivotal mediator of inflammatory response. In the first part of this …

The protective efficacy of serum antibodies results from the interplay of antigen-specific B
cell clones of different affinities and specificities. These cellular dynamics underlie serum …

COVID-19 is associated with a wide range of clinical manifestations, including autoimmune
features and autoantibody production. Here we develop three protein arrays to measure IgG …

In the past 15 years, B cells have been rediscovered to be not merely bystanders but rather
active participants in autoimmune aetiology. This has been fuelled in part by the clinical …

It has been more than three decades since the first monoclonal antibody was approved by
the United States Food and Drug Administration (US FDA) in 1986, and during this time …

Neutralizing antibodies can block infection, clear pathogens, and are essential to provide
long-term immunity. Since the onset of the pandemic, SARS-CoV-2 neutralizing antibodies …

Although critical illness has been associated with SARS-CoV-2–induced hyperinflammation,
the immune correlates of severe COVID-19 remain unclear. Here, we comprehensively …

The realization that autoantibodies can contribute to dysfunction of the brain has brought
about a paradigm shift in neurological diseases over the past decade, offering up important …